FDA Priority Review for Post-Neoadjuvant T-DXd in HER2+ Early BC
The FDA granted Priority Review to trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease, signaling a potential new standard to reduce recurrence risk.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.